Residency · Residency · Critical Care

Obstetric Emergencies in the ICU

Physiological Changes of Pregnancy

Key Physiological Changes of Pregnancy

Cardiovascular

Understanding the normal physiological adaptations of pregnancy is essential for the critical care physician, as these changes fundamentally alter the interpretation of vital signs, laboratory values, and hemodynamic parameters. Blood volume increases by 40 to 50 percent by term, representing an expansion of 1.5 to 2 liters above non-pregnant values. This expansion serves to meet the metabolic demands of the fetoplacental unit and to provide a buffer against the hemorrhage that inevitably accompanies delivery.

Cardiac output increases by 30 to 50 percent, peaking at 28 to 32 weeks of gestation, driven by both increased heart rate (which rises 10 to 20 bpm above baseline) and increased stroke volume. Systemic vascular resistance decreases by 20 to 30 percent due to progesterone-mediated vasodilation and the low-resistance placental circulation, producing a decrease in blood pressure during the first and second trimesters that returns toward baseline by term.

Aortocaval compression syndrome is a critically important consideration in the third trimester. The gravid uterus compresses the inferior vena cava and aorta in the supine position, reducing venous return and cardiac output by up to 30 percent. This mandates left lateral decubitus positioning or left uterine displacement for all pregnant patients beyond 20 weeks of gestation, particularly during resuscitation. Physiological anemia of pregnancy results from the greater expansion of plasma volume relative to red blood cell mass, producing hemodilution with a hemoglobin nadir of 11 to 12 g/dL at 28 to 32 weeks.

Respiratory

The respiratory system undergoes progesterone-driven adaptations that significantly alter ventilatory mechanics and gas exchange. Tidal volume increases by 30 to 40 percent, producing an increase in minute ventilation of 30 to 50 percent. This drives PaCO2 down to 28 to 32 mmHg, creating a chronic respiratory alkalosis with compensatory metabolic acidosis (bicarbonate 18 to 22 mEq/L). Functional residual capacity decreases by 20 percent due to diaphragmatic elevation by the gravid uterus. This reduced FRC, combined with increased oxygen consumption (up 20 percent), critically diminishes the oxygen reserve, causing pregnant patients to desaturate far more rapidly during apnea than non-pregnant patients. The normal arterial blood gas in pregnancy reflects these changes: pH 7.40 to 7.45, PaCO2 28 to 32, HCO3 18 to 22, PaO2 100 to 105 mmHg.

Hematologic

Pregnancy produces a hypercoagulable state through increases in fibrinogen (to 400 to 600 mg/dL), Factor VII, Factor VIII, and Factor X, with a concomitant decrease in protein S. This hypercoagulability increases VTE risk 5 to 6 fold over the non-pregnant state, with the highest risk occurring in the postpartum period. The interpretation of fibrinogen levels must account for the elevated pregnancy baseline: a fibrinogen level below 200 mg/dL is abnormal in pregnancy and represents DIC, whereas this level might be considered normal outside of pregnancy. Gestational thrombocytopenia is common and benign when the platelet count remains above 70,000/mcL, but a count below 100,000/mcL requires investigation for pathological causes.

Renal

Renal blood flow and glomerular filtration rate increase by 40 to 65 percent in pregnancy, producing a decrease in serum creatinine to a normal pregnancy range of 0.4 to 0.6 mg/dL. This is a critically important reference shift: a creatinine of 0.8 mg/dL, which would be entirely normal outside of pregnancy, represents significant renal impairment in the pregnant patient. Physiological hydronephrosis, more prominent on the right than the left, is a normal finding and should not be mistaken for obstructive uropathy.

Preeclampsia and Eclampsia

Definitions

Preeclampsia is defined as new-onset hypertension (blood pressure at or above 140/90 mmHg after 20 weeks of gestation) combined with proteinuria (greater than 300 mg in 24-hour collection) or, in the absence of proteinuria, with evidence of end-organ dysfunction. Preeclampsia with severe features is diagnosed when any of the following are present: blood pressure at or above 160/110 mmHg, platelet count below 100,000/mcL, serum creatinine above 1.1 mg/dL or doubling of baseline, liver transaminases more than twice normal, pulmonary edema, or new-onset cerebral or visual symptoms.

Eclampsia is defined as the occurrence of generalized tonic-clonic seizures in a patient with preeclampsia, or unexplained new-onset seizures in the context of preeclamptic features. HELLP syndrome is a severe variant characterized by hemolysis (elevated LDH above 600, schistocytes, elevated indirect bilirubin), elevated liver enzymes, and low platelets (below 100,000/mcL).

Management of Severe Preeclampsia/Eclampsia

Magnesium sulfate is the drug of choice for both seizure prophylaxis and treatment in preeclampsia and eclampsia, supported by the landmark MAGPIE trial which demonstrated a 58 percent reduction in eclampsia risk (NNT of 63 for all preeclampsia, NNT of 8 for severe preeclampsia). The loading dose is 4 to 6 g IV over 15 to 20 minutes, followed by a maintenance infusion of 1 to 2 g/hr. The therapeutic level is 4 to 8 mEq/L (4.8 to 9.6 mg/dL). Monitoring must include serial assessment of deep tendon reflexes (lost at magnesium levels of 8 to 12 mEq/L), respiratory rate (depression occurs at 12 to 15 mEq/L), and urine output. The antidote for magnesium toxicity is calcium gluconate 1 g IV over 3 minutes.

Antihypertensive therapy targets a blood pressure range of 140-155/90-105 mmHg, deliberately avoiding precipitous reductions that could compromise uteroplacental perfusion. First-line agents include IV labetalol in an escalating regimen (20 mg bolus, then 40 mg, then 80 mg at 10 to 15 minute intervals, to a maximum of 300 mg), IV hydralazine (5 to 10 mg every 20 minutes, maximum 30 mg), or oral nifedipine (10 to 20 mg every 20 to 30 minutes). Nicardipine infusion at 5 to 15 mg/hr is available for refractory hypertension. ACE inhibitors and ARBs are absolutely contraindicated due to teratogenicity, and nitroprusside must be avoided because of fetal cyanide toxicity.

Delivery is the definitive treatment for preeclampsia and eclampsia. At 37 weeks or beyond, delivery is indicated. Between 34 and 37 weeks with severe features, delivery should proceed after stabilization. Before 34 weeks with severe features, the goal is to stabilize the mother, administer antenatal corticosteroids (betamethasone 12 mg IM for two doses 24 hours apart) for fetal lung maturation, and deliver if the maternal condition worsens or fetal status becomes non-reassuring.

<image>Preeclampsia management algorithm. Entry: "Suspected preeclampsia (BP >=140/90 after 20 weeks + proteinuria or organ dysfunction)." First branch: Assess for severe features (BP >=160/110, platelets <100K, Cr >1.1, elevated LFTs >2x, pulmonary edema, visual/cerebral symptoms, HELLP). Without severe features: monitor closely, deliver at 37 weeks, low-dose aspirin if <37 weeks. With severe features: (1) Start magnesium sulfate 4-6 g IV load then 1-2 g/hr; (2) Treat BP with IV labetalol or hydralazine, target 140-155/90-105; (3) Labs: CBC, CMP, LDH, coagulation, UA; (4) If <34 weeks: antenatal steroids + assess stability for 24-48 hours; (5) If >=34 weeks or unstable at any GA: deliver. Eclampsia pathway: same protocol plus seizure management with repeat magnesium 2 g IV bolus if seizures occur, then delivery after stabilization. Include HELLP criteria box and magnesium monitoring sidebar (reflexes, RR, urine output, toxicity levels and calcium antidote).</image>

Obstetric Hemorrhage

Postpartum Hemorrhage (PPH)

Postpartum hemorrhage, defined as blood loss exceeding 500 mL after vaginal delivery or 1000 mL after cesarean delivery, is the leading cause of maternal mortality worldwide. The etiologies are systematically organized using the mnemonic of the 4 T's: Tone (uterine atony, accounting for 70 to 80 percent of PPH and representing the most common cause), Tissue (retained placenta or placental fragments), Trauma (lacerations, hematomas, uterine rupture, uterine inversion), and Thrombin (coagulopathy from DIC or pre-existing bleeding disorders).

Uterotonic Agents for PPH

Management of Uterine Atony

Management of uterine atony follows a stepwise escalation of interventions. Bimanual uterine massage is the immediate first intervention and should be performed without delay. Uterotonics are administered in a stepped approach: first, oxytocin at 20 to 40 units in 1 liter of normal saline at 200 mL/hr or 10 units intramuscularly; second, methylergonovine (Methergine) at 0.2 mg IM every 2 to 4 hours, which must be avoided in patients with hypertension due to its vasoconstrictive properties; third, carboprost (Hemabate, 15-methyl PGF2-alpha) at 0.25 mg IM every 15 minutes to a maximum of 2 mg, which is contraindicated in asthma; and fourth, misoprostol at 800 to 1000 mcg rectally or sublingually when other agents are unavailable.

Tranexamic acid at 1 g IV within 3 hours of delivery was evaluated in the WOMAN trial, which demonstrated reduced death from bleeding (NNT of 267), establishing TXA as a standard component of PPH management. Intrauterine balloon tamponade using devices such as the Bakri balloon or Ebb device provides temporizing hemostasis. Surgical options include uterine compression sutures (B-Lynch suture) and uterine artery embolization by interventional radiology. Hysterectomy is the definitive treatment for life-threatening hemorrhage refractory to all other measures.

Placenta Accreta Spectrum (PAS)

Placenta accreta spectrum disorders represent a continuum of abnormal placental invasion: accreta (invasion into the myometrium), increta (invasion through the myometrium), and percreta (invasion through the serosa, potentially into adjacent organs). Risk factors include prior cesarean delivery and placenta previa. Management requires a planned cesarean hysterectomy at 34 to 36 weeks with a multidisciplinary team including obstetrics, gynecologic oncology, urology, vascular surgery, and anesthesiology. Massive hemorrhage should be anticipated, with the massive transfusion protocol activated and cell salvage equipment available.

Massive Transfusion in Obstetrics

The principles of massive transfusion in obstetrics parallel those in trauma, with balanced 1:1:1 ratio blood product administration. A critical distinction is the higher fibrinogen target in pregnancy: replacement should be triggered at a fibrinogen level below 200 mg/dL (not 150 mg/dL as in non-obstetric settings), reflecting the elevated physiological baseline. O-negative packed red blood cells and AB-positive FFP should be used for emergent transfusion when type-specific blood is not yet available. TXA within 3 hours is supported by the WOMAN trial evidence.

Amniotic Fluid Embolism (AFE)

Pathophysiology

Amniotic fluid embolism is a rare (1 to 12 per 100,000 deliveries) but catastrophic obstetric emergency carrying a mortality of 20 to 60 percent. Despite its name, AFE is not primarily a mechanical embolic event but rather an anaphylactoid immune response triggered by the entry of fetal material into the maternal circulation. Complement activation and the release of vasoactive mediators produce a biphasic hemodynamic response. Phase 1, occurring within minutes, involves acute right ventricular failure from severe pulmonary vasoconstriction, producing profound hypoxia. Phase 2, developing over hours, involves left ventricular failure and the development of DIC with hemorrhage.

Clinical Presentation

AFE presents as sudden cardiovascular collapse during labor, delivery, or the immediate postpartum period. The classic triad consists of hypoxia, hypotension, and coagulopathy (DIC). Preceding symptoms may include restlessness, anxiety, and dyspnea. DIC develops in 80 percent of patients who survive the initial cardiovascular collapse. Cardiac arrest occurs in 87 percent of cases.

Management

There is no specific treatment for AFE; management is entirely supportive. The A-FAST approach provides a memory aid: Atropine for bradycardia, Fluids, Advanced cardiac life support, Supportive care, and Transfusion. Aggressive hemodynamic support with vasopressors, inotropes, and volume resuscitation is essential. DIC should be managed with massive transfusion protocol activation, cryoprecipitate, and platelets. If cardiac arrest occurs at 20 weeks or greater gestation, perimortem cesarean delivery should begin within 4 to 5 minutes. VA-ECMO should be considered for refractory cardiovascular collapse. Inhaled nitric oxide or epoprostenol may be used for severe pulmonary hypertension and right ventricular failure.

Perimortem Cesarean Delivery

Indications and Timing

Perimortem cesarean delivery is indicated for maternal cardiac arrest at 20 weeks of gestation or beyond, when the uterus is at or above the level of the umbilicus. The decision to incise must be made within 4 minutes of arrest onset, with the goal of delivery by 5 minutes. This intervention serves a dual purpose: it improves the chances of neonatal survival, and critically, it improves the effectiveness of maternal resuscitation by relieving aortocaval compression, thereby increasing venous return and cardiac output during CPR and reducing maternal oxygen consumption.

The procedure should not be delayed for transport to an operating room; it should be performed at the bedside if necessary. CPR must not be stopped to perform the cesarean; chest compressions should continue throughout the procedure and after delivery.

CPR Modifications in Pregnancy

Cardiopulmonary resuscitation in pregnancy requires specific modifications. Left uterine displacement, achieved through manual displacement of the uterus or a 15 to 30 degree left lateral tilt, must be maintained throughout resuscitation to relieve aortocaval compression. Chest compression hand placement should be slightly higher on the sternum due to the elevated diaphragm. Standard ACLS medications and defibrillation energies should be used without dose reduction. Fetal monitors should be removed as they interfere with defibrillation. Intravenous access should be established above the diaphragm, as IVC compression limits the effectiveness of lower extremity venous access.

Acute Fatty Liver of Pregnancy (AFLP)

Features

Acute fatty liver of pregnancy is a rare condition (1 in 7,000 to 15,000 pregnancies) that typically presents in the third trimester, with associations including primigravida status, male fetal sex, and multiple gestation. The underlying pathology is microvesicular steatosis producing acute hepatic failure. The clinical presentation progresses from nausea, vomiting, abdominal pain, and jaundice to coagulopathy, encephalopathy, and hypoglycemia.

Laboratory findings include moderately elevated transaminases (typically 200 to 500, rarely exceeding 1000), elevated bilirubin, DIC with low fibrinogen, hypoglycemia, elevated ammonia, and leukocytosis. The Swansea criteria require 6 of 11 features for diagnosis. The distinction from HELLP syndrome is clinically important: AFLP characteristically produces hypoglycemia, low fibrinogen (DIC), and hepatic encephalopathy, while HELLP is characterized by hemolysis and typically higher transaminase levels.

Management

Delivery is the definitive treatment and should proceed regardless of gestational age once the diagnosis is confirmed. Supportive measures include continuous dextrose infusion (D10W) to prevent hypoglycemia, FFP and cryoprecipitate for DIC, empiric NAC, and ICU-level monitoring. The prognosis is generally favorable, with most patients recovering within 1 to 2 weeks of delivery; liver transplantation is rarely necessary. Importantly, the infant should be screened for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genetic disorder of mitochondrial fatty acid oxidation that has a recognized association with maternal AFLP.

Sepsis in Pregnancy

Unique Considerations

Recognizing sepsis in pregnancy is challenging because the normal physiological changes of pregnancy mimic early sepsis signs. Baseline tachycardia, lower blood pressure, and leukocytosis (normal WBC up to 15,000, reaching 30,000 during labor) make standard screening tools unreliable. The qSOFA and SOFA scores are poorly validated in the pregnant population. Common sources of obstetric sepsis include chorioamnionitis, endometritis, pyelonephritis, pneumonia, and septic abortion. Obstetric sepsis mortality is 5 to 10 percent, often caused by group A streptococcus or E. coli.

Management

The management principles follow the Surviving Sepsis Campaign framework: early antibiotics, fluid resuscitation, and vasopressors when needed. Antibiotic selection should provide coverage for group A and group B streptococci, E. coli, and anaerobes, with piperacillin-tazobactam or cefepime plus metronidazole as typical empiric regimens, adding vancomycin when MRSA is suspected. Source control is essential and may include delivery for chorioamnionitis, dilation and curettage for retained products of conception, or drainage of abscess. Left lateral positioning should be maintained during resuscitation. Continuous fetal monitoring should be performed when the fetus is viable, with delivery considered for non-reassuring fetal status.

<image>Obstetric cardiac arrest management algorithm. Entry: "Maternal cardiac arrest recognized." Simultaneous actions shown in parallel tracks: Track 1 (Maternal ACLS): left uterine displacement, standard ACLS (chest compressions slightly higher, IV access above diaphragm, standard drug doses and defibrillation energy), remove fetal monitors. Track 2 (Perimortem cesarean preparation): if >=20 weeks gestation (uterus at/above umbilicus), call OB/neonatal team, prepare for bedside delivery. Decision point at 4 minutes: if no ROSC → begin perimortem cesarean immediately (goal: delivery by 5 minutes). Continue maternal CPR during and after delivery. Post-delivery: neonatal resuscitation team manages infant; continue maternal ACLS; reassess for ROSC (aortocaval compression relief may restore circulation). If ROSC achieved → standard post-cardiac arrest care with obstetric and ICU teams. Include annotation that perimortem cesarean benefits BOTH mother (improves CPR effectiveness) and infant.</image>

Key Clinical Pearls

• A creatinine of 0.8 mg/dL is ABNORMAL in pregnancy (normal 0.4-0.6) — this represents significant renal impairment
• Fibrinogen <200 mg/dL is ABNORMAL in pregnancy (normal 400-600) — this represents DIC and requires urgent replacement
• Always position the pregnant patient (>20 weeks) in left lateral decubitus or with left uterine displacement to prevent aortocaval compression
• Magnesium sulfate is the drug of choice for both seizure prophylaxis and treatment in eclampsia — not phenytoin or benzodiazepines
• Perimortem cesarean delivery should begin within 4 minutes of maternal cardiac arrest at >= 20 weeks — it benefits both mother and infant
• Avoid ACE inhibitors, ARBs, and nitroprusside in pregnancy — use labetalol, hydralazine, or nifedipine for hypertensive emergencies
• Tranexamic acid reduces death from PPH when given within 3 hours (WOMAN trial) — include in every obstetric hemorrhage protocol
• AFLP is distinguished from HELLP by the presence of hypoglycemia, low fibrinogen, and hepatic encephalopathy — delivery is the definitive treatment for both

References

1. ACOG Practice Bulletin No. 222. Gestational hypertension and preeclampsia. Obstet Gynecol. 2020;135(6):e237-e260.
2. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN). Lancet. 2017;389(10084):2105-2116.
3. Althaus JE, Breaker SB, Clark SL. Amniotic fluid embolism. Obstet Gynecol. 2016;128(2):e51-e62.
4. Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. Circulation. 2015;132(18):1747-1773.
5. Knight M, Nelson-Piercy C, Kurinczuk JJ, et al. A prospective national study of acute fatty liver of pregnancy in the UK. Gut. 2008;57(7):951-956.

Read this lecture as Markdown